In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry.

Silvano EspositoPasquale PaglianoGiuseppe De SimoneAmedeo GuarinoAngelo PanPaola BrambillaClaudio MastroianniMiriam LichtnerPierluigi BrugnaroAnna CarrettaTeresa SantantonioGaetano BrindicciGiuliana CarregaFrancesca MontagnaniGiuseppe LapadulaAnna SpoltiRoberto LuzzatiElisabetta SchiaroliVittoria ScaglioneCarlo PallottoDanilo TacconiFrancesco QuintieriEnrico Trecarichinull null

Published in: Infection (2024)

In conclusion, by virtue of its PK/PD properties, dalbavancin represents a valuable option to daily in-hospital intravenous or outpatient antimicrobial regimens also for off-label indications requiring a long-term treatment of Gram-positive infections.

Keyphrases

staphylococcus aureus
healthcare
physical activity
gram negative
open label
high dose
quality improvement
clinical trial
multidrug resistant
adverse drug
low dose
replacement therapy